Clinicopathologic implication of ezrin expression in non-small cell lung cancer
- Abstract
- Background Ezrin, a member of the ezrin-radixin-moesin family, is implicated in tumor progression, metastatic dissemination, and adverse outcomes, in several cancer types. In this study, we explored the clinicopathological significance of ezrin expression in non-small cell lung carcinomas (NSCLCs).
Methods Immunohistochemical analysis of tissue microarray with 112 surgically resected NSCLC specimens, was performed to examine the ezrin expression. We also correlated ezrin expression with other clinicopathological features and prognosis.
Results The ezrin-positive group revealed significantly higher correlation with pleural invasion (p=0.016) and pathologic stage (p=0.050). Univariate survival analysis showed that ezrin-positive group had a significantly shorter cancer-specific survival than ezrin-negative group (p=0.016). Meanwhile, female (p=0.030), no pleural invasion (p=0.023), no lymphatic invasion (p=0.026), and early pathologic stage (p=0.008) significantly correlated with longer survival. Multivariate survival analysis showed that variables such as ezrin positivity (p=0.032), female (p=0.035), and early pathologic stage (p=0.001) were independent prognostic factors for NSCLC.
Conclusions Ezrin might be a molecular marker to predict poor prognosis of NSCLC.
- All Author(s)
- H. W. Lee
; E. H. Kim
; M. H. Oh
- Issued Date
- 2012
- Type
- Article
- Keyword
- Carcinoma, non-small cell lung; Ezrin; Prognosis
- Publisher
- 대한병리학회
대한세포병리학회
The Korean Society of Pathologists
The Korean Society for Cytopathology
- ISSN
- 1738-1843
; 2092-8920
- Citation Title
- Korean journal of pathology
- Citation Volume
- 46
- Citation Number
- 5
- Citation Start Page
- 470
- Citation End Page
- 477
- Language(ISO)
- eng
- DOI
- 10.4132/KoreanJPathol.2012.46.5.470
- URI
- http://schca-ir.schmc.ac.kr/handle/2022.oak/2947
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.